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S.S. Hosseini-Asl, H. Akhavan
Genetics, Ardabil University of Medical Sciences, Ardabil, Iran
Background:Gastric cancer (GC) as the fourth common cancer over the world and
responsible for the second cause of cancer-related deaths, has high incidence rate in
Iran and especially in its North-Western province, Ardabil. In this study, the circulating
hTERTmRNA and DNAwere studied in patients affected with GC in Ardabil.
Methods:Using conventional PCR and RT-PCR, Q-PCR andQ-RT-PCR, evaluating
the circulating hTERT nucleic acids in the plasma samples of the 100 GC cases and the
same number of sex-, age-, and residence place adjusted healthy volunteers, as the con-
trol group has been done.
Results: The circulating hTERTmRNA level in patients was higher (40X) than the con-
trols. In the case of circulating DNA, cases had higher difference (65X). These findings
have been evaluated as significant difference. There were no significant relationships
between hTERT level and age groups or adenocarcinoma type among cases.
Conclusions: The elevated hTERTmRNA/ DNA plasma level among patients indicates
the accuracy of the proposed subjects. However, performing cohort studies on circulat-
ing hTERTmRNA is advised.
Legal entity responsible for the study: Ardabil University of Medical Sciences.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background:More than 50% of melanomas harbor BRAF V600mutations and can be
treated with targeted therapy. Circulating tumor DNA (ctDNA) harbors the same
genetic alterations as a tumor origin. The analysis of ctDNA provides diagnostic and
prognostic information before, during treatment and at progression. For detection
mutations in ctDNA droplet digital PCR (ddPCR)most often are used. This method is
very analytically sensitive, but expensive and time-consuming.
Methods:We developed a biochip for simultaneous detection six somatic BRAFmuta-
tions (V600E [c.1799T>A], V600E [c.1799_1800delTGinsAA], V600M, V600K,
V600R, V600D) in small amount of ctDNA. For preferable amplification of mutated
overWTDNAwe used nested LNA clamp PCR. PCR fragments were labeled via incor-
poration of Cy5-dTTP during the second round of PCR and hybridized with specific
oligonucleotides immobilized on a biochip. Method allows detecting 0.05%mutated
DNA in a background ofWTDNA.We tested 35 ctDNA samples frommelanoma
patients. The ctDNAwas isolated from 2-5ml of plasma. For 10 patients plasma col-
lected prior to surgical intervention. For 25 patients plasma collected during antitumor
therapy. For all patients we knew BRAF status in tumor.
Results:All ctDNA samples were tested by biochip assay and droplet digital PCR (in
duplicate). For each assay we used 5 ll of ctDNA. The concordance of results was
observed in 32/35 samples. In two cases mutations were detected only by biochip assay.
These samples were collected prior surgical intervention and tumor DNA from these
patients harbored coincident mutations. In one case mutation V600E was detected by
biochip assay, but in ddPCR result we detected one positive drop in each repetition, but
this isn’t enough to consider this sample V600E-positive. In general, ctDNA BRAF sta-
tus strong correlated with tumor status and disease progression.
Conclusions: The biochip assay is a sensitive method for BRAFmutation detection in
ctDNA. This method can be useful in diagnosis and treatment monitoring of mela-
noma patients. In addition, the biochip assay has the potential for multiplex analysis in
contrast to ddPCR. It is very important for the study of small amounts of ctDNA.
Legal entity responsible for the study: Engelhardt Institute of Molecular Biology.
Funding: This work was supported by Grant of the President of the Russian Federation
(#MK-2519.2017.4).
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Background: Circulating cell-free DNA (cfDNA) analysis can serve as a powerful diag-
nostic tool. However, most of the modern techniques used in oncology nowadays are
based on expensive NGS procedures on the nuclear DNA. Here we propose a new
approach for the development of cheap diagnostic tests based on cfDNA fragmentation
profiles.
Methods:We used NGS data from cfDNA to obtain the coverage distribution by frag-
ments of different lengths on healthy donors and patients with colorectal cancer. Based
on fragments joint positioning we developed a method for selecting the characteristic
and reference genome regions. The reference region was chosen as the area where the
coverage levels have the greatest positive correlation between cancer samples and con-
trols. The characteristic region is the region with the highest negative correlation
between cancer patients and healthy individuals. Characteristic regions were chosen
nearby the transcription start site (TSS) of the gene transcripts with the greatest expres-
sion difference between colorectal cancer samples and controls. In the end, we eval-
uated the results of the in silico qPCR in the selected regions to predict the diagnostic
value of the characteristic and reference fragments.
Results:We found several cfDNA biomarkers in the suppressor genes, among them
KIF1B, LPAR1, APC, FN1, SEPT9. The results obtained from in silico qPCR on the
selected loci coincided with the expected patterns.
Conclusions: The developed model for the detection of the characteristic cancer-
specific loci based on the cfDNA analysis can be used as a design tool for the simple
qPCR diagnostics systems.
Legal entity responsible for the study:Atlas Oncodiagnostics, LLS.
Funding: Atlas Oncodiagnostics, LLS.
Disclosure: All authors have declared no conflicts of interest.
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Background: Primary or acquired resistance to trastuzumab limits targeted treatment
efficacy. Circulating tumor (ct)DNA is a potential surrogate to tissue that overcomes
intratumoral heterogeneity with a minimal invasive approach.We assessed genomic
alterations (GAs) of ctDNA and demonstrated molecular changes during trastuzumab
therapy.
Methods: Prospective genomic profiling of longitudinal plasma samples from seven
HER2-positive metastatic gastric cancer (GC) patients treated with trastuzumab-based
chemotherapy, using the AVENIO ctDNA Surveillance targeted gene panel and specifi-
cally assessing ERBB2 andMET copy number variations (CNVs) status.
Results: ctDNA sequencing data was available for four patients both at baseline and
progression. At baseline, 75% of GAs identified were single nucleotide variations
(SNVs), including commonmutated genes such as TP53 (12.5%), PIK3CA (12.5%),
KRAS (12.5%), andMET (12.5%). Twenty-five per cent were copy number variations
(CNVs), specifically ERBB2 amplification. At progression, almost the majority of GAs
were acquired (45.5%). MET amplification was the most frequently detected GA
(26.7% of cases). ERBB2 amplification (13.3%),MET (13.3%), TP53 (6.7%), PIK3CA
(6.7%), and ERBB2 (6.7%)mutations were other co-occurring GAs.
Conclusions: Follow-up ctDNA profiling during trastuzumab treatment identifies
emergence of MET amplification andmutations, as a potential biomarker of resistance.
Legal entity responsible for the study: Research Ethics Committee of Hospital del
Mar.
Funding: Roche.
Disclosure: All authors have declared no conflicts of interest.
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